Prostate cancer: to screen or not to screen? (Q34571878)

3 August 2017

1 reference

title

Prostate cancer: to screen or not to screen? (English)

1 reference

3 August 2017

1 reference

1

D E Neal

1 reference

3 August 2017

J L Donovan

2

1 reference

3 August 2017

publication date

1 September 2000

1 reference

Lancet Oncology Commission

3 August 2017

published in

1 reference

3 August 2017

volume

1

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

17-24

1 reference

Geographic pathology of latent prostatic carcinoma

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(09)70279-7

7 January 2021

Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(09)70279-7

7 January 2021

Rate of relapse following treatment for localized prostate cancer: a critical analysis of retrospective reports

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(09)70279-7

7 January 2021

Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(09)70279-7

7 January 2021

Immunoperoxidase localization of prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(09)70279-7

7 January 2021

Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(09)70279-7

7 January 2021

An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(09)70279-7

7 January 2021

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(09)70279-7

7 January 2021

PSAdynia and other PSA-related syndromes: a new epidemic--a case history and taxonomy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(09)70279-7

7 January 2021

Prostate cancer incidence and mortality in the United States and the United Kingdom

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(09)70279-7

7 January 2021

Asymptomatic incidence and duration of prostate cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(09)70279-7

7 January 2021

The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(09)70279-7

7 January 2021

Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(09)70279-7

7 January 2021

Prostate carcinoma incidence and patient mortality: the effects of screening and early detection.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(09)70279-7

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(09)70279-7

7 January 2021

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(09)70279-7

7 January 2021

10.1016/S1470-2045(09)70279-7

Identifiers

DOI

1 reference

3 August 2017

1 reference